CervoMed (CRVO) to Release Quarterly Earnings on Friday

Key Points

• CervoMed (CRVO) is set to release its Q2 2025 earnings results on August 8th, with analysts predicting a loss of ($0.55) per share and revenue of $1.45 million.
• The company recently reported a loss of ($0.56) EPS in its last quarter, surpassing estimates, while analysts expect an average of ($2 EPS for both the current and next fiscal years.
• CervoMed has been rated a "Moderate Buy" with an average target price of $21.50, while various analysts have recently adjusted their target prices between $10.00 and $27.00.

CervoMed (NASDAQ:CRVO - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Friday, August 8th. Analysts expect the company to announce earnings of ($0.55) per share and revenue of $1.45 million for the quarter.

CervoMed (NASDAQ:CRVO - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.04. CervoMed had a negative net margin of 200.57% and a negative return on equity of 44.07%. The business had revenue of $1.92 million for the quarter, compared to analyst estimates of $1.70 million. On average, analysts expect CervoMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CervoMed Price Performance

NASDAQ CRVO traded up $0.46 on Monday, hitting $9.29. The stock had a trading volume of 100,444 shares, compared to its average volume of 2,199,214. The business's fifty day moving average price is $7.35 and its 200 day moving average price is $6.71. CervoMed has a 52-week low of $1.80 and a 52-week high of $20.63. The stock has a market cap of $80.80 million, a price-to-earnings ratio of -4.27 and a beta of -0.79.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on CRVO shares. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price target on shares of CervoMed in a report on Friday, July 25th. Canaccord Genuity Group boosted their price objective on shares of CervoMed from $21.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Finally, Chardan Capital boosted their price objective on shares of CervoMed from $14.00 to $15.00 and gave the company a "buy" rating in a report on Monday, May 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $21.50.

Institutional Investors Weigh In On CervoMed

A hedge fund recently bought a new stake in CervoMed stock. AQR Capital Management LLC bought a new stake in shares of CervoMed Inc. (NASDAQ:CRVO - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 24,846 shares of the company's stock, valued at approximately $227,000. AQR Capital Management LLC owned 0.29% of CervoMed at the end of the most recent reporting period. 25.15% of the stock is currently owned by institutional investors and hedge funds.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.